Company intelligence / Profile preview
Brii Biosciences
Beijing, Beijing, Chinabriibio.com ↗
- Ownership
- Public · 2137.HK
- Development stage
- Other
01
Overview
Brii Biosciences has advanced its core hepatitis B functional cure program with multiple ongoing Phase 2b trials. Key assets include BRII-179—a recombinant protein-based immunotherapeutic vaccine—BRII-835/elebsiran—an siRNA targeting HBV—and BRII-877/tobevibart—a broadly neutralizing monoclonal antibody. Recent data show promising immune responses and antiviral effects in chronic HBV patients. The company has received Breakthrough Therapy Designations for all three main assets in China. Other pipeline programs in CNS disorders and HIV have been deprioritized as the company focuses on late-stage development of curative regimens for chronic hepatitis B
- Therapeutic areas
- PsychiatryInfectious Diseases
- Modalities
- Small interfering RNA (siRNA)Recombinant protein-based immunotherapeutics (therapeutic vaccines)Monoclonal antibodies (mAbs)Long-acting injectables
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Vir Biotechnology Inc .(co-development/licensing of elebsiran ,tobevibart )VBI Vaccines Inc .(licensing of BRII –179 )
04
Financials
- Market cap
- $95.7M
- Total revenue
- $2.7M
- Enterprise value
- $-168.8M
Beyond the preview
Go deeper on Brii Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Brii Biosciences.